These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29071508)

  • 21. Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.
    Valenzano KJ; Khanna R; Powe AC; Boyd R; Lee G; Flanagan JJ; Benjamin ER
    Assay Drug Dev Technol; 2011 Jun; 9(3):213-35. PubMed ID: 21612550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy.
    Janovick JA; Stewart MD; Jacob D; Martin LD; Deng JM; Stewart CA; Wang Y; Cornea A; Chavali L; Lopez S; Mitalipov S; Kang E; Lee HS; Manna PR; Stocco DM; Behringer RR; Conn PM
    Proc Natl Acad Sci U S A; 2013 Dec; 110(52):21030-5. PubMed ID: 24324164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemical and pharmacological chaperones as new therapeutic agents.
    Loo TW; Clarke DM
    Expert Rev Mol Med; 2007 Jun; 9(16):1-18. PubMed ID: 17597553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological chaperones correct misfolded GPCRs and rescue function: protein trafficking as a therapeutic target.
    Maya-Núñez G; Ulloa-Aguirre A; Janovick JA; Conn PM
    Subcell Biochem; 2012; 63():263-89. PubMed ID: 23161143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SLC6 Transporter Folding Diseases and Pharmacochaperoning.
    Freissmuth M; Stockner T; Sucic S
    Handb Exp Pharmacol; 2018; 245():249-270. PubMed ID: 29086036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protein misfolding diseases: Prospects of pharmacological treatment.
    Gámez A; Yuste-Checa P; Brasil S; Briso-Montiano Á; Desviat LR; Ugarte M; Pérez-Cerdá C; Pérez B
    Clin Genet; 2018 Mar; 93(3):450-458. PubMed ID: 28671287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The many functions of the endoplasmic reticulum chaperones and folding enzymes.
    Halperin L; Jung J; Michalak M
    IUBMB Life; 2014 May; 66(5):318-26. PubMed ID: 24839203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological Chaperones: Design and Development of New Therapeutic Strategies for the Treatment of Conformational Diseases.
    Convertino M; Das J; Dokholyan NV
    ACS Chem Biol; 2016 Jun; 11(6):1471-89. PubMed ID: 27097127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological chaperone action on G-protein-coupled receptors.
    Bernier V; Bichet DG; Bouvier M
    Curr Opin Pharmacol; 2004 Oct; 4(5):528-33. PubMed ID: 15351360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological chaperones as therapeutics for lysosomal storage diseases.
    Boyd RE; Lee G; Rybczynski P; Benjamin ER; Khanna R; Wustman BA; Valenzano KJ
    J Med Chem; 2013 Apr; 56(7):2705-25. PubMed ID: 23363020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assistance for Folding of Disease-Causing Plasma Membrane Proteins.
    Juarez-Navarro K; Ayala-Garcia VM; Ruiz-Baca E; Meneses-Morales I; Rios-Banuelos JL; Lopez-Rodriguez A
    Biomolecules; 2020 May; 10(5):. PubMed ID: 32392767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chaperoning osteogenesis: new protein-folding disease paradigms.
    Makareeva E; Aviles NA; Leikin S
    Trends Cell Biol; 2011 Mar; 21(3):168-76. PubMed ID: 21183349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Second-Generation Pharmacological Chaperones: Beyond Inhibitors.
    Tran ML; Génisson Y; Ballereau S; Dehoux C
    Molecules; 2020 Jul; 25(14):. PubMed ID: 32660097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases.
    Sánchez-Fernández EM; García Fernández JM; Mellet CO
    Chem Commun (Camb); 2016 Apr; 52(32):5497-515. PubMed ID: 27043200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ER chaperone-metal interactions: links to protein folding disorders.
    Tiffany-Castiglioni E; Qian Y
    Neurotoxicology; 2012 Jun; 33(3):545-57. PubMed ID: 22370090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological chaperone approaches for rescuing GPCR mutants: Current state, challenges, and screening strategies.
    Beerepoot P; Nazari R; Salahpour A
    Pharmacol Res; 2017 Mar; 117():242-251. PubMed ID: 28027910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological chaperones: potential treatment for conformational diseases.
    Bernier V; Lagacé M; Bichet DG; Bouvier M
    Trends Endocrinol Metab; 2004 Jul; 15(5):222-8. PubMed ID: 15223052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The oxidoreductase behavior of protein disulfide isomerase impedes fold maturation of endoplasmic reticulum-processed proteins in the pivotal structure-coupled step of oxidative folding: implications for subcellular protein trafficking.
    Gonzalez V; Pal R; Narayan M
    Biochemistry; 2010 Jul; 49(29):6282-9. PubMed ID: 20568731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptors.
    Ulloa-Aguirre A; Michael Conn P
    Recent Pat Endocr Metab Immune Drug Discov; 2011 Jan; 5(1):13-24. PubMed ID: 22074574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular chaperone functions in protein folding and proteostasis.
    Kim YE; Hipp MS; Bracher A; Hayer-Hartl M; Hartl FU
    Annu Rev Biochem; 2013; 82():323-55. PubMed ID: 23746257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.